Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil

  • W.Y. Cheung Tom Baker Cancer Centre
  • P. Kavan McGill University
  • A. Dolley Taiho Pharma Canada Inc
Keywords: real world evidence, RWE, trifluridine/tipiracil, FTD/TPI, TAS-102, refractory, QoL, symptoms, mCRC, metastatic colorectal cancer, pain


Background Quality of life (qol) is important for oncology patients, especially for those with late-stage disease. The present study was initiated to address the lack of published prospective data about the qol benefits of trifluri­dine/tipiracil (tfd/tpi) compared with best supportive care (bsc) in patients with refractory metastatic colorectal cancer (mcrc).

Methods This prospective, cross-sectional, non-interventional study used multidimensional validated scales to evaluate patient-reported qol in two study cohorts of patients and also to measure differences in mcrc-related symptoms and pain in a real-world clinical setting.

Results Our findings demonstrate that patients with refractory mcrc report better overall qol when treated with tfd/ tpi than with bsc alone. In that population, statistically significant differences in mean qol measures favoured tfd/tpi over bsc for physical symptom distress, psychological distress, activity impairment, overall valuation of life, and symptomatology. The overall better qol for patients receiving tfd/tpi implies that treatment was well tolerated and was associated with a lower symptom burden. No significant differences for pain were observed between the groups.

Conclusions This study suggests that tfd/tpi is a well-tolerated option for the treatment of patients with refractory mcrc, showcasing the value of capturing real-world qol data in routine clinical practice.

Author Biographies

W.Y. Cheung, Tom Baker Cancer Centre

Section of Medical Oncology

P. Kavan, McGill University

Department of Oncology, Faculty of Medicine

How to Cite
Cheung, W., Kavan, P., & Dolley, A. (2020). Quality of life in a real-world study of patients with metastatic colorectal cancer treated with trifluridine/tipiracil. Current Oncology, 27(5). https://doi.org/10.3747/co.27.6533
Medical Oncology